-
Search Underway for 'Dooars Rani' Tigress After Second Escape from Buxa Tiger Reserve
-
Teatro Mayor Unveils 152-Performance 2027 Season Highlighting Beethoven and García Márquez
-
The Dilemma of Recording Live Music: Preserving Memories vs. Being Present
-
Rutgers Defeats NJIT 101-64 Behind Francis and Mark Scores
-
AmeriLife Welcomes Finance Veteran Richard Dziadzio as Chief Financial Officer; Names Jim Quinn President & Chief Transformation Officer
-
6 Pieces of Furniture Worth Investing In
-
Fulcrum Metals PLC Announces New Critical Mineral Recoveries Expand Potential
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 11
-
Guardian Metal Resources PLC Announces Proposed Spin-Out of Non-Tungsten Projects
-
Fulcrum Metals PLC Announces Publication of Updated Investor Presentation
-
THIEAUDIO Introduces Clairvoyance MKII: The Evolution of a Signature Sound
-
Christmas Day Shifts More than Double as Americans Return to In-Person Holiday Celebrations
-
BlackBerry to Participate in Upcoming Investor Conferences
-
NiobiumX Mining Reports Results of Ground Radiometric Survey at Shipshaw, Maps Two Distinct Radiometric Signatures Across the Core Claims, and Moves to a High-Resolution Airborne Survey of the Full 2,686-Hectare Package
-
Irving Resources Reports on Drilling in Yamagano Mining Right at the Yamagano Joint Venture, Kyushu, Japan
-
Trifecta Gold Reports 2026 Exploration Results from the Liam and Lois Projects, Tombstone Gold Belt, Yukon
-
XCF Global Hosts USDA at New Rise Renewables Reno as Facility Surpasses 4.4 Million Gallons Since Restart
-
5E Advanced Materials to Host Fiscal First Quarter 2027 Earnings Conference Call on November 17, 2026
-
Patriot Software Adds Performance Reviews to Patriot HR
-
Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
-
Healixa's FrostPulse(TM) Technology Solves a Major Roadblock to Data Center Growth: Cooling Without the Water Burden
-
Route1 Announces 2026 Annual Meeting Results
-
NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
-
Ethur Takes On Hiring Fraud With Facial Biometrics Identity Checks and Connected Payroll and Bank Data
-
PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
-
Green Leaf Innovations (OTC: GRLF) Meets OTCID Disclosure Requirements Following Profitable Q2 2026 Results
-
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
-
Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets
-
Thukukile Zuma Resigns from ANC Johannesburg Leadership Amid Disciplinary Dispute
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
-
Mahayuti-backed Rajesh Patil Elected Chairman of Gokul Dairy Amidst Political Deadlock
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
Cardiff Lexington Announces Planned Retirement of Daniel Thompson as Chairman of the Board of Directors
- President and CEO of Cardiff Lexington, Alex Cunningham, to succeed Daniel Thompson as Chairman -
LEXINGTON, KY / ACCESS Newswire / December 29, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that Daniel Thompson will retire from his position as Chairman of the Board of Directors, effective December 31, 2025, after 25 years of dedicated service. Alex Cunningham, President and Chief Executive Officer of Cardiff Lexington, will succeed Mr. Thompson as Chairman.
As Chairman, Mr. Thompson has played a significant role in building Cardiff Lexington into a diversified healthcare-focused organization through multiple strategic transformations, acquisitions, and periods of growth. During his leadership, Cardiff Lexington has expanded its footprint and strengthened its operational platform. The Company is now positioned for the next phase of its development including the continued geographical expansion of its operating subsidiary, Nova Ortho and Spine, and the targeted uplisting of the Company's stock to a major US exchange.
"It has been a great honor to serve as Chairman of the Board of Directors for Cardiff Lexington," said Mr. Thompson. "This Company has been more than a career to me - it has been a calling. After 25 years, the time has come for me to step back, but I do so with immense pride in what we have built together and deep gratitude to our employees, partners, and shareholders who made it possible. I leave knowing the Company is in extraordinary hands and have complete confidence in our President and CEO Alex Cunningham and in the team at Cardiff Lexington."
Effective upon Mr. Thompson's retirement, Alex Cunningham, the Company's current President and CEO, will assume the additional role of Chairman of the Board of Directors. Mr. Cunningham has served as Chief Executive Officer of Cardiff Lexington for the last ten years and has played an instrumental role in shaping the Company's strategy and operations, as well as driving numerous successful growth initiatives.
"On behalf of Cardiff Lexington's management team and Board of Directors, I would like to extend our sincerest gratitude to Daniel for his years of dedicated service and contributions," Mr. Cunningham commented. "Daniel leaves this post with the business positioned for considerable growth in 2026 and beyond. Our operating subsidiary, Nova Ortho and Spine, has exceeded our expectations in 2025, and is expanding its footprint and reputation as a premier provider of orthopedic healthcare services. As we continue to grow, the next step in our trajectory is to uplist our stock to a major US exchange to enhance our visibility among a larger and more qualified pool of investors."
Daniel Thompson's Message to Shareholders
"To our investors who have stood by me over the past 25 years, I want to sincerely thank you for your trust and support," Thompson said. "It has been a pleasure getting to know many of you and communicating with you on a regular basis over the years. I am deeply grateful for those relationships. While I will always value them, it is now time for me to say goodbye.
Mr. Thompson will remain a supporter and shareholder of the Company and looks forward to retirement and personal pursuits.
Mr. Thompson concluded, "Going forward, I encourage you to reach out to IMS Investor Relations at the phone number and email address at the end of this press release, who will be available to answer any questions and support you as Cardiff Lexington continues its journey."
About Cardiff Lexington Corporation
Cardiff Lexington Corporation (OTCQB: CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.
All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.
For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.
Investor Contact
Cardiff Lexington Investor Relations
[email protected]
(800) 375-2349
Or
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: Cardiff Lexington Corporation
View the original press release on ACCESS Newswire
P.Martin--AMWN